Intensive early and sustained lowering of non–high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry
The lowest achieved levels both at 2 months and at 1 year of non-HDL-C were associated with better outcome. The lowest risk was observed when target was achieved within 2 months of MI and sustained thereafter. These findings challenge the current stepwise approach for cholesterol lowering after MI, which inevitably results in delaying goal attainment and possible harm.
Authors
- Angelo Modica
- Kausik Kumar Ray (ORCID: https://orcid.org/0000-0003-0508-0954)
- Johan Westerbergh (ORCID: https://orcid.org/0000-0003-1076-6045)
- Emil Hagström (ORCID: https://orcid.org/0000-0003-3221-0144)
- Margrét Leósdóttir (ORCID: https://orcid.org/0000-0003-1677-1566)
- Jessica R. Schubert (ORCID: https://orcid.org/0000-0002-1917-5885)
- Bertil Lindahl (ORCID: https://orcid.org/0000-0002-5795-0061)
- Nilo B. Cater (ORCID: https://orcid.org/0000-0001-5868-8643)
- Jonas Brinck (ORCID: https://orcid.org/0000-0002-1230-6205)
- Håkan Melhus (ORCID: https://orcid.org/0000-0002-6857-5973)
Institutions
- Uppsala University (SE)
- Pfizer (United States) (US)
- Malmö University (SE)
- Lund University (SE)
- Karolinska Institutet (SE)
- Pfizer (Sweden) (SE)
- Skåne University Hospital (SE)
- Imperial College London (GB)
Publication Details
- Journal
- European Heart Journal
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1093/eurheartj/ehae576
- Citations
- 47
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 26.92
Funders
- Pfizer
- National Institute for Health and Care Research
- Hjärt-Lungfonden
- Uppsala Universitet
- Landstinget i Uppsala län
- Region Uppsala